Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Citation(s) in RCA

0
(from Reference Citation Analysis)

Indexed Articles

Ranked By

Impact Index Per Article
Citation(s) in RCA

Article Statistics

Refine

MESH Headings

Show more Refine

First Author

Show more Refine

Authors

Show more Refine

Publication Titles

Show more Refine

Grant Agencies

Show more Refine

Countries/Regions

Show more Refine

Affiliations

Show more Refine

Category

Show more Refine

For: Choe JH, Abdel-Azim H, Padula WV, Abou-el-Enein M. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. JAMA Netw Open 2022;5:e2245956. [PMID: 36520440 PMCID: PMC9856352 DOI: 10.1001/jamanetworkopen.2022.45956] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open

For:	Choe JH, Abdel-Azim H, Padula WV, Abou-el-Enein M. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. JAMA Netw Open 2022;5:e2245956. [PMID: 36520440 PMCID: PMC9856352 DOI: 10.1001/jamanetworkopen.2022.45956] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open

No articles found.

(The first 100,000 artilces are displayed in RCA.)